证券代码：688277 证券简称：天智航 公告编号：2026-008 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司2025年年 度报告中披露的数据为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：万元 注：1.本报告期初数同法定披露的上年年末数。 2.以上财务数据及指标以合并报表数据填列，但未经审计，最终结果以公司2025年年度报告为准。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 报告期内，公司实现营业收入28,325.76万元，较上年同期增加58.38%；归属于母公司所有者的净利润 亏损18,403.18万元，较上年同期亏损扩大51.93 %；归属于母公司所有者的扣除非经常性损益的净利润 亏损21,953.72万元，较上年同期亏损扩大29.33%。 2026年2月28日 报告期末，公司总资产172,340.41万元，较报告期初增加1.87%；归属于母公司的所有者 ...

证券日报网讯 2月27日，天智航发布公告称，公司2025年实现营业收入28325.76万元，同比增长 58.38%；归属于母公司所有者的净利润亏损18403.18万元，亏损同比扩大51.93%。 （文章来源：证券日报） ...

格隆汇2月27日丨天智航(688277.SH)公布2025年度业绩快报，报告期内，公司实现营业收入28,325.76万 元，较上年同期增加58.38%；归属于母公司所有者的净利润亏损18,403.18万元，较上年同期亏损扩大 51.93%；归属于母公司所有者的扣除非经常性损益的净利润亏损21,953.72万元，较上年同期亏损扩大 29.33%。 报告期内，公司营业利润较上年同期减少6,152.69万元，亏损同比扩大61.96%；利润总额较上年同期减 少6,132.35万元，亏损同比扩大61.60%。报告期内归属于母公司所有者的净利润较上年同期减少 6,290.21万元，亏损同比扩大51.93%。主要原因为：投资收益较上年同期有较大幅度减少；因实施限制 性股票激励计划，股份支付费用较上年同期有较大幅度增长；冲回以前年度确认的亏损部分的递延所得 税费用，导致所得税费用较上年同期有所增长。 ...

天智航表示，报告期内，公司投资收益较上年同期有较大幅度减少；因实施限制性股票激励计划，股份 支付费用较上年同期有较大幅度增长；冲回以前年度确认的亏损部分的递延所得税费用，导致所得税费 用较上年同期有所增长。 北京商报讯（记者 丁宁）2月27日晚间，天智航（688277）发布2025年度业绩快报显示，报告期内，公 司实现营业收入约为2.83亿元，同比增长58.38%；归属净利润约为-1.84亿元。 ...

证券代码：688277 证券简称：天智航 公告编号：2026-008 北京天智航医疗科技股份有限公司 2025 年度业绩快报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投资者注意投资 风险。 一、2025 年度主要财务数据和指标 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 28,325.76 | 17,884.26 | 58.38 | | 营业利润 | -16,082.55 | -9,929.86 | 不适用 | | 利润总额 | -16,087.29 | -9,954.94 | 不适用 | | 归属于母公司所有者的净利润 | -18,403.18 | -12,112.97 | 不适用 | | 归属于母公司所有者的扣除非 经常性损益的净利润 | -21,953.72 | -16, ...

天智航发布业绩快报，2025年度实现营业总收入2.83亿元，同比增长58.38%。净利润亏损1.84亿元，上 年同期亏损1.21亿元。主要原因为：投资收益较上年同期有较大幅度减少；因实施限制性股票激励计 划，股份支付费用较上年同期有较大幅度增长；冲回以前年度确认的亏损部分的递延所得税费用，导致 所得税费用较上年同期有所增长。 ...

华银健康生活主题灵活配置（001056）成立日期2015年3月27日，最新规模7577.66万。今年以来收益 20.43%，同类排名364/8891；近一年收益23.33%，同类排名4141/8137；成立以来收益38.5%。 华银健康生活主题灵活配置（001056）基金经理为庞文杰。 2月27日，天智航涨5.11%，截至发稿，报25.92元/股，成交2.24亿元，换手率1.98%，总市值118.19亿 元。 资料显示，北京天智航医疗科技股份有限公司位于北京市海淀区建枫路(南延)中关村西三旗金隅科技园 8号院2号楼，成立日期2010年10月22日，上市日期2020年7月7日，公司主营业务涉及专注于骨科手术导 航定位机器人的研发、生产、销售和服务。主营业务收入构成为：骨科手术导航定位机器人58.31%， 配套设备及耗材23.86%，技术服务16.49%，其他(补充)1.31%，其他0.04%。 从基金十大重仓股角度 数据显示，华银基金管理旗下1只基金重仓天智航。华银健康生活主题灵活配置（001056）四季度减持3 万股，持有股数20万股，占基金净值比例为4.01%，位居第十大重仓股。根据测算，今日浮盈赚取约 2 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [5] Core Insights - The underlying logic of the current pharmaceutical industry era is innovation and international expansion, with a focus on innovative drugs and technology-driven sectors [2][3] - The report highlights the strong performance of the CRO market and suggests a dual investment strategy focusing on both "0 to 1" technology innovation and low-position stocks [2][3] - The report emphasizes the ongoing trend of BD (Business Development) transactions in innovative drugs, with significant growth expected in 2026 [4][15] Summary by Sections 1. Key Events in the Pharmaceutical Industry During the Spring Festival - Innovative drug BD transactions have seen a strong start, with significant overseas development and registration progress for key products [13][14] - The total amount of BD transactions for innovative drugs in China for 2026 has already surpassed one-third of the total for 2025 [15] - The revision of the National Essential Medicines List Management Measures may signal changes in the essential medicines directory [28] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical sector's performance was relatively weak, with a weekly decline of 0.81%, ranking 20th among all industries [34][38] - The total trading volume for pharmaceuticals was 401.12 billion yuan, accounting for 3.83% of the total market, below the historical average of 7.09% [55] - The report notes a rising valuation level for the pharmaceutical industry, with a PE ratio of 29.25, which is below the historical average [52] 3. Stock Performance Review - The report lists the top-performing stocks, including Dongyangguang and Zhendemedical, while highlighting the underperformers like Huayuan Biology and *ST Sailong [58][59]

Group 1 - Tianzhihang Medical Technology Co., Ltd. experienced a stock price increase of 5.43%, reaching 26.19 CNY per share, with a trading volume of 165 million CNY and a turnover rate of 1.42%, resulting in a total market capitalization of 11.942 billion CNY [1] - The company, established on October 22, 2010, and listed on July 7, 2020, focuses on the research, production, sales, and service of orthopedic surgical navigation robots [1] - The revenue composition of the company includes: orthopedic surgical navigation robots (58.31%), supporting equipment and consumables (23.86%), technical services (16.49%), and other (1.31%) [1] Group 2 - Galaxy Fund holds a significant position in Tianzhihang, with the Galaxy Kangle Stock A fund (519673) owning 467,900 shares, representing 5% of the fund's net value, making it the ninth-largest holding [2] - The Galaxy Kangle Stock A fund has a current size of 141 million CNY and has achieved a year-to-date return of 18.34%, ranking 89 out of 5,569 in its category [2] - The fund manager, Fang Wei, has been in charge for 4 years and 280 days, with the fund's total assets amounting to 576 million CNY, and the best and worst returns during his tenure being 2.42% and -12.24%, respectively [2]

Group 1 - Tianzhihang's stock price fell by 2.36% to 24.84 yuan per share, with a total market capitalization of 11.327 billion yuan, and a cumulative decline of 8.17% over three consecutive days [1] - The company, Beijing Tianzhihang Medical Technology Co., Ltd., focuses on the research, production, sales, and service of orthopedic surgical navigation robots, with main business revenue composition: 58.31% from navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [1] Group 2 - E Fund's ETF, E Fund National Robot Industry ETF (159530), entered Tianzhihang's top ten circulating shareholders, holding 10.7803 million shares, accounting for 2.38% of circulating shares, with a floating loss of approximately 6.4682 million yuan today [2] - The E Fund National Robot Industry ETF has a total scale of 15.267 billion yuan, with a year-to-date return of 0.81% and a one-year return of 20.43% [2] - Fund managers Li Shujian and Li Xu have managed the fund for 2 years and 3 years respectively, with the best returns during their tenure being 118.55% and 166.96% [2]